Lemalesomab Biosimilar – Anti-NCA-90 mAb – Research Grade from ProteoGenix; catalogue PX-TA1200; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Lemalesomab Biosimilar, also known as Anti-NCA-90 monoclonal antibody (mAb), is a research grade therapeutic antibody that targets the NCA-90 antigen. This biosimilar is a highly specific and potent tool for studying and targeting NCA-90, making it a valuable addition to the scientific community. In this article, we will delve into the structure, activity, and potential applications of Lemalesomab Biosimilar.
Lemalesomab Biosimilar is a monoclonal antibody that is produced using recombinant DNA technology. It is a biosimilar of the original Lemalesomab, which was developed as a therapeutic antibody for treating acute respiratory distress syndrome (ARDS). The biosimilar version has the same amino acid sequence and structure as the original Lemalesomab, making it a highly similar and interchangeable alternative.
The antibody is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions of both the heavy and light chains are responsible for binding to the NCA-90 antigen.
Lemalesomab Biosimilar specifically targets the NCA-90 antigen, which is a glycoprotein expressed on the surface of neutrophils, monocytes, and macrophages. This antigen is involved in the adhesion and migration of immune cells, making it a crucial therapeutic target for various inflammatory and autoimmune diseases.
The binding of Lemalesomab Biosimilar to NCA-90 inhibits the adhesion of immune cells to the endothelial cells, thus reducing inflammation and tissue damage. It also promotes the phagocytosis of immune cells, leading to the clearance of pathogens and damaged cells. These activities make Lemalesomab Biosimilar a potent anti-inflammatory and immunomodulatory agent.
Lemalesomab Biosimilar has a wide range of potential applications in both research and therapeutic settings. Its specific targeting of the NCA-90 antigen makes it a valuable tool for studying the role of this antigen in various diseases. It can also be used to develop diagnostic assays for detecting NCA-90 expression levels in different cell types.
In terms of therapeutic applications, Lemalesomab Biosimilar has the potential to treat various inflammatory and autoimmune diseases, such as ARDS, rheumatoid arthritis, and inflammatory bowel disease. Its ability to modulate the immune response and reduce inflammation makes it a promising candidate for these conditions.
Moreover, Lemalesomab Biosimilar can also be used in combination with other therapeutic agents to enhance their efficacy. For example, it can be used in combination with chemotherapy drugs to increase the phagocytic activity of immune cells, leading to better clearance of cancer cells.
In summary, Lemalesomab Biosimilar is a highly specific and potent therapeutic antibody that targets the NCA-90 antigen. Its structure, activity, and potential applications make it a valuable tool for scientific research and a promising candidate for the treatment of various inflammatory and autoimmune diseases. With its interchangeable biosimilar version, Lemalesomab Biosimilar offers an affordable and accessible option for researchers and clinicians alike.
ProteoGenix catalogue number PX-TA1200. For research use only.
Target: Lemalesomab Biosimilar – Anti-NCA-90 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Lemalesomab Biosimilar – Anti-NCA-90 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
